Genomic alterations – a Brave New World for cancer treatment?
New meeting on genomics in cancer treatment
The advent of genome sequencing is bringing about a quiet revolution in healthcare. Yet while the thirst for advanced genomic knowledge may seem enticing, doctors know that information without interpretation may not be very useful.
We are pleased to announce a new high-level scientific meeting that explores ways to better use existing research data in order to improve clinical oncologists’ personalised treatment programs for cancer patients.
The 2nd edition of the Molecular Analysis for Personalised therapy meeting (MAP) will be held 23-24 September in London, diving into the most pressing issues in this field.
• What are the actionable genomic alterations in frequent cancers?
• How can we define rules to identify drivers in individuals?
• What are the latest emerging technologies for personalised medicine?
• What can we learn from recent trials?
Medical oncologists, interns, academics, regulators, industry R&D reps and investigators are invited to register for this important gathering to discuss clinical interpretation of molecular tests for metastatic cancers.
A joint initiative of Cancer Research UK, UNICANCER and ESMO, this conference shines a light on the latest medical developments in a constantly evolving field.
Jean-Charles Soria, Gustave Roussy, Villejuif, France
Charles Swanton, The Francis Crick Institute, UK
Fabrice André, Gustave Roussy, Villejuif, France
Ian Walker, Director of Clinical Research & Strategic Partnerships, Cancer Research UK